Poorly Differentiated Neuroendocrine Rectal Carcinoma with Uncommon Immune-histochemical Features and Clinical Presentation with a Subcutaneous Metastasis, Treated with First Line Intensive Triplet Chemotherapy Plus Bevacizumab FIr-B/FOx Regimen: An...
Overview
Authors
Affiliations
Background: Neuroendocrine tumors (NETs) are heterogeneous, widely distributed tumors arising from neuroendocrine cells. Gastrointestinal (GI)-NETs are the most common and NETs of the rectum represent 15, 2% of gastrointestinal malignancies. Poorly differentiated neuroendocrine carcinomas of the GI tract are uncommon. We report a rare case of poorly differentiated locally advanced rectal neuroendocrine carcinoma with nodal and a subcutaneous metastasis, with a cytoplasmic staining positive for Synaptophysin and Thyroid Transcription Factor-1.
Case Presentation: A 72-year-old male presented to hospital, due to lumbar, abdominal, perineal pain, and severe constipation. A whole-body computed tomography scan showed a mass of the right lateral wall of the rectum, determining significant reduction of lumen caliber. It also showed a subcutaneous metastasis of the posterior abdominal wall. Patient underwent a multidisciplinary evaluation, diagnostic and therapeutic plan was shared and defined. The pathological examination of rectal biopsy and subcutaneous nodule revealed features consistent with small-cell poorly differentiated neuroendocrine carcinoma. First line medical treatment with triplet chemotherapy and bevacizumab, according to FIr-B/FOx intensive regimen, administered for the first time in this young elderly patient affected by metastatic rectal NEC was highly active and tolerable, as previously reported in metastatic colo-rectal carcinoma (MCRC). A consistent rapid improvement in clinical conditions were observed during treatment. After 6 cycles of treatment, CT scan and endoscopic evaluation showed clinical complete response of rectal mass and lymph nodes; patient underwent curative surgery confirming the pathologic complete response at PFS 9 months.
Discussion And Conclusions: This case report of a locally advanced rectal NEC with an unusual subcutaneous metastasis deserves further investigation of triplet chemotherapy-based intensive regimens in metastatic GEP NEC.
Wang Q, Yin R, Tang W, Li C, Zheng H, Zhang X Zhejiang Da Xue Xue Bao Yi Xue Ban. 2022; 51(5):594-602.
PMID: 36581574 PMC: 10264974. DOI: 10.3724/zdxbyxb-2021-0387.
Bruera G, DAndrilli A, Simmaco M, Guadagni S, Rendina E, Ricevuto E Front Oncol. 2020; 10:1155.
PMID: 32850329 PMC: 7417602. DOI: 10.3389/fonc.2020.01155.
Squamous cell anal cancer: Management and therapeutic options.
Pessia B, Romano L, Giuliani A, Lazzarin G, Carlei F, Schietroma M Ann Med Surg (Lond). 2020; 55:36-46.
PMID: 32461801 PMC: 7240186. DOI: 10.1016/j.amsu.2020.04.016.